Company intelligence / Profile preview

Navire Pharma

Palo Alto, California, United Statesnavirepharma.com ↗

Ownership: Public · BBIO
Employees: ~20
Development stage: Phase 1

Overview

BBP-398, Navire's SHP2 inhibitor, is currently being evaluated in multiple clinical studies. Preclinical data showed potential for their SHP2 inhibitor to treat lung cancer tumor cells that have acquired resistance to EGFR inhibitors.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

BBP-398

Phase 1/2

Indications: Advanced solid tumors, Non-small cell lung cancer

Partnerships

Bristol Myers SquibbLianBioAmgenMD Anderson Cancer Center

Beyond the preview

Go deeper on Navire Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Navire Pharma.

Explore the full profile